Kenneth Ho shared a link.

Director of BEAMSTART

China's MicuRx Pharma secures $107m in Series E round

China Merchants Securities, Korea Investment Partners, Yingke PE, Founder H Fund, Zhongtai Ventures, and Detong Capital joined the round. 

  • MicuRx attracted a slew of investors including China Merchants Group’s investment bank unit China Merchants Securities, Korea Investment Partners, Yingke PE, Founder Securities’ investment arm Founder H Fund, Zhongtai Ventures, and Detong Capital.
  • The fresh proceeds will be used for new drug development, global clinical trials, pipeline advancement and drug commercialisation in China, the company said.
  • MicuRx completed its $43-million Series D round in August 2020 led by Huagai Capital with the participation of Sinopharm-CICC and Zero2IPO Asset Management.

DEALSTREETASIA.COM24 Dec, 2020

BEAMSTART is a hub for everything Startups, Entrepreneurship, and Innovation. Connect with a global community of people, and stay updated with the latest startup jobs, news, and discussions.

 
© 2016 - 2022 BEAMSTART. All Rights Reserved (Legal).